Drug intelligence / Profile preview

TG-MVA

Development stage: Preclinical
Lead developer: Transgene
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

TG-MVA is a preclinical-stage prophylactic viral vector vaccine being developed by Transgene for the prevention of Mpox (formerly monkeypox). The vaccine is based on the **Modified Vaccinia Ankara (MVA)** platform, a highly attenuated, non-replicating poxvirus vector known for its safety profile and ability to induce robust cellular and humoral immune responses. Unlike traditional MVA vaccines often produced in chicken embryo fibroblasts, TG-MVA is derived from a specific cell line, which is intended to facilitate large-scale, standardized manufacturing. The vaccine aims to induce protective immunity against the Mpox virus to prevent infection and disease transmission.

Beyond the preview

Go deeper on TG-MVA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TG-MVA.

Explore the full profile